Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]

Amino Acid Mix Supercharges Lipid Nanoparticle Delivery for mRNA and CRISPR Therapies

Scientists have discovered that a simple mix of three amino acids can greatly improve how well lipid‑nanoparticle (LNP)–based therapies work in the body. These LNPs are tiny fat‑like packages used to carry mRNA or CRISPR components into cells, and they are already at the heart of new vaccines and gene‑editing treatments. The new finding suggests […]

pre|CISION Platform Update: AVA6103 Outperforms Leading ADC, Phase 1 Dosing Imminent

Since October 2025, when the pre|CISION platform first demonstrated its potential to deliver dual payloads like MMAE and exatecan from a single molecule in prostate cancer models, significant new data has emerged that strengthens its case as a next-generation targeted therapy. The platform’s ability to exploit fibroblast activation protein (FAP) in the tumor microenvironment for […]

Evolutionary Oncology: A New Research Validates This Approach in Preclinical Models

Researchers at Trinity College Dublin and Moffitt Cancer Center have uncovered a promising prostate cancer breakthrough: radiation-resistant tumor cells become unexpectedly vulnerable to attack by natural killer (NK) immune cells, presenting a strategic “evolutionary double-bind” that could transform treatment approaches. This discovery challenges traditional views of therapy resistance, showing that when prostate cancer cells adapt […]

Ultrasound Nanobubbles Crack Prostate Cancer’s Collagen Fortress Improving Immunotherapy Penetration

Researchers at Case Western Reserve University used tiny ultrasound-activated nanobubbles to dismantle the tough collagen walls that shield solid tumors from treatments. These “fortresses” made of stiff, crosslinked collagen block immune cells and drugs from reaching cancer cells deep inside, a major hurdle in fighting aggressive tumors like prostate cancer. The nanobubbles, filled with inert […]

KLS-3021 An Oncolytic Viral Therapy For Prostate Cancer Could Soon Reach Clinical Trial Stage

KLS-3021 represents a promising advancement in oncolytic virus therapy, particularly for prostate cancer, where it has shown potential to address unmet needs in early and locally advanced disease. This recombinant vaccinia virus is engineered to selectively infect and lyse tumor cells while delivering a triple payload of therapeutic genes: PH-20 hyaluronidase to degrade the tumor’s […]

Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue

Scientists at Oregon State University have pioneered a groundbreaking nanomaterial that selectively annihilates cancer cells by harnessing the tumors’ own hostile chemical environment, while leaving healthy tissues completely unscathed. This innovative approach, detailed in a recent study published in Advanced Functional Materials, represents a major leap in chemodynamic therapy (CDT), an emerging treatment strategy that […]

Nanotech Advancement: Relief from Prostate Cancer Bone Pain on the Horizon

A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]

SHR-A1921: A Next-Generation TROP2-Targeted Antibody-Drug Conjugate Shows Promise in Prostate Cancer

SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]

Recent Discovery on tRNA Halves in Prostate Cancer

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer. […]